Skip to main content
OpenTrials
Completed

NCT Number: NCT02204059

Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer

The primary objectives of this study is to assess the safety and tolerability of intravenously (i.v.) administered 186 Rhenium-isotope (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of 186 Re-labelled bivatuzumab in patients with non-small cell lung cancer (NSCLC)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma, Non-Small-Cell Lung Bronchial Neoplasms Carcinoma, Bronchogenic Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have histological or cytological confirmation of Non small cell lung cancer (NSCLC) stage I, II or IIIa according to the staging system of the American Joint Committee on Cancer (AJCC)
  • Patients destined for resection of the tumour
  • Patients over 18 years of age
  • Patients younger than 80 years of age
  • Patients who had given 'written informed consent'
  • Patients with a life expectancy of at least 3 months
  • Patients with a good performance status: Karnofsky > 60

Exclusion criteria

  • Life-threatening infection, allergic diathesis, organ failure (bilirubin > 30µmol/l and/or creatinine > 150 µmol/l) or evidence of a recent myocardial infarction on Electrocardiogram (ECG) or unstable angina pectoris
  • Pre-menopausal women (last menstruation <= 1 year prior to study start)
  • Not surgically sterile (hysterectomy, tubal ligation) and
  • Not practicing acceptable means of birth control, (or not planned to be continued throughout the study). Acceptable methods of birth control include oral, implantable or injectable contraceptives
  • Women with a positive serum pregnancy test at baseline
  • White blood cell count < 3000/mm³, granulocyte count < 1500/mm³ or platelet count < 100000/mm³. Details of prior chemotherapy and radiotherapy had to be known.
  • Hematological disorders, congestive heart failure, bronchial asthma, alimentary or contact allergy, severe atopy or allergy

Treatment and study plan

hMAb BIWA 4

Drug

Primary outcomes

  1. Number of patients with adverse events

    Time frame: up to 6 weeks post infusion

  2. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 6 weeks post infusion

  3. Number of patients with clinically significant changes in vital signs

    Time frame: up to 6 weeks post infusion

  4. Presence of Human-Anti-Human-Antibody (HAHA)

    Time frame: up to 6 weeks post infusion

  5. Biodistribution of 186Re-labelled hMAb BIWA 4 in tumour and normal tissue samples

    Time frame: up to 96 hours post infusion

    assessed by radioimmunoscintigraphy expressed as no, low, medium or high

  6. Uptake of 186Re-labelled hMAb BIWA 4 in tumour and normal tissue samples

    Time frame: after surgery on day 8

    Biodistribution assessed from biopsy sample as percentage of the injected dose per kg tissue (%ID/kg)

  7. AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: up to 6 weeks post infusion

  8. Cmax (Maximum measured concentration of the analyte in plasma)

    Time frame: up to 6 weeks post infusion

  9. tmax (Time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 6 weeks post infusion

  10. t½ (Terminal half-life of the analyte in plasma)

    Time frame: up to 6 weeks post infusion

  11. MRT (Mean residence time of the analyte in the body)

    Time frame: up to 6 weeks post infusion

  12. Vss (Apparent volume of distribution under steady state conditions)

    Time frame: up to 6 weeks post infusion

  13. Vz (Apparent volume of distribution during the terminal phase)

    Time frame: up to 6 weeks post infusion

  14. CL (Total body clearance)

    Time frame: up to 6 weeks post infusion

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Non-small Cell Lung Cancer

Important dates

Study start
1999
Primary completion
2001
First posted
Jul 30, 2014
Registry last updated
Jul 30, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.